Delamanid Resistance: Update and Clinical Management

Delamanid, a-first-in-class bicyclic nitroimidazole, was recently approved for multidrug-resistant tuberculosis treatment. Pitted against the hope for improving treatment outcomes is the threat of the rapid resistance emergence. This review provides information on the mechanisms of action, resistanc...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Clinical infectious diseases Ročník 71; číslo 12; s. 3252
Hlavní autori: Nguyen, Thi Van Anh, Anthony, Richard M, Cao, Thi Thu Huyen, Bañuls, Anne-Laure, Nguyen, Van Anh Thi, Vu, Dinh Hoa, Nguyen, Nhung Viet, Alffenaar, Jan-Willem C
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 15.12.2020
Predmet:
Antitubercular Agents - pharmacology
Antitubercular Agents - therapeutic use
Humans
Microbial Sensitivity Tests
Mycobacterium tuberculosis - genetics
Nitroimidazoles - therapeutic use
Oxazoles - therapeutic use
Tuberculosis, Multidrug-Resistant - drug therapy
delamanid
drug susceptibility testing
drug resistance
pharmacokinetics/pharmacodynamics
tuberculosis
ISSN:1537-6591, 1537-6591
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Delamanid, a-first-in-class bicyclic nitroimidazole, was recently approved for multidrug-resistant tuberculosis treatment. Pitted against the hope for improving treatment outcomes is the threat of the rapid resistance emergence. This review provides information on the mechanisms of action, resistance emergence, and drug susceptibility testing (DST) for delamanid. Delamanid resistance has already been reported in both in vitro experiments and clinical settings. Although mutations conferring delamanid resistance have been identified in fbiA, fbiB, fbiC, ddn, and fgd1 genes of Mycobacterium tuberculosis, knowledge about the molecular resistance mechanisms is limited, and there remains no standardized DST method. The rapid acquisition of delamanid resistance emphasizes the need for optimal use of new drugs, the need for drug resistance surveillance, and a comprehensive understanding of drug resistance mechanisms. Further studies are necessary to investigate genetic and phenotypic changes that determine clinically relevant delamanid resistance to help develop a rapid delamanid DST.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1537-6591
1537-6591
DOI:10.1093/cid/ciaa755